To date adeno-associated viral (AAV) vectors are the only gene therapy vectors that have been shown to efficiently transduce photoreceptor cells and have thus become the most commonly used vector for ocular transduction. Various AAV serotypes have been evaluated in the eye, the first of which was AAV2, which is able to transduce photoreceptors, retinal pigment epithelium (RPE) and retinal ganglion cells. AAV serotypes 1 and 4, as well as AAV2 pseudotyped with these capsids, only transduce the RPE. AAV serotype 5 and AAV2/5 transduce the photoreceptors as well as RPE, but not retinal ganglion cells. Here, we assessed the capacity of the novel serotype AAV2/8 to transduce various ocular tissues of the adult murine retina by administering AAV2/8 green fluorescent protein intravitreally, subretinally and intracamerally. We also determined the kinetics and efficiency of self-complementary AAV (scAAV) vectors of serotypes 2/2, 2/5 and 2/8 and compared them with single-stranded AAV (ssAAV). We found that ssAAV2/8 transduces photoreceptors and RPE more efficiently than ssAAV2/2 and ssAAV2/5, and that scAAV2/8 had faster onset and higher transgene expression than ssAAV2/8. This improved transduction efficiency might facilitate the development of improved gene therapy protocols for inherited retinal degenerations, particularly those caused by defects in photoreceptor-specific genes.
Recombinant adeno-associated viral vectors (rAAV) have been used extensively to deliver therapeutic transgenes to a variety of target cells in the eye. AAV vectors are promising vehicles for gene transfer as they are replication deficient, have a wide host range, are not associated with human disease, can transduce post-mitotic cells and have shown stable long-term transgene expression. 1, 2 AAV genomes are linear single-stranded DNA approximately 4.7 kb in length. Wild-type virus and recombinant vector particles contain either plus or minus strands. 3 The main advantage for the use of AAV in the eye, however, is its unique ability to transduce photoreceptor cells efficiently. There are now several primary isolates of AAV, which have been shown to have different transduction profiles in the eye. rAAV2, the most commonly used serotype, transduces both photoreceptors and retinal pigment epithelium (RPE) following subretinal injection and transduces ganglion cells after intravitreal administration. Transgene expression is detectable 2-3 weeks after subretinal injection, peaking after 6-8 weeks. 4 Subretinal injection of rAAV5 transduces both RPE and photoreceptors faster and with higher efficiency than rAAV2, but following intravitreal injection rAAV5 does not transduce retinal ganglion cells. 5 Chimaeric vectors can also be made by cross-packing transgene AAV2 inverted terminal repeats (ITRs) into the capsid of another serotype, for example AAV2/5 shows the same photoreceptor transduction profile as AAV5, both in terms of the rate of reporter gene expression (2 weeks vs 3-4 weeks post-injection, p.i.) and the number of cells transduced.
6 AAV2/1, 2/4 and 2/6 in contrast favour selective transduction of RPE cells only, with AAV2/1-mediated green fluorescent protein (GFP) expression after 24-48 h of vector administration. 5, [7] [8] [9] Key factors that influence the kinetics of transduction are now being elucidated. First, entry to the cell begins with serotypespecific receptor-mediated endocytosis, after which AAV is made transduction 'competent' by priming for nuclear transport and/or uncoating within the endosome. 10 The rate of virus particle uncoating is thought to play a significant role in the kinetics of transgene expression and this depends on the type of capsid.
11 Upon uncoating, a single-stranded (ss) genome is either rapidly degraded or stabilized by forming a double-stranded, transduction efficient molecule by de novo synthesis of a complementary strand or by annealing to one. 12 We manipulated the AAV genome to contain two copies of the transgene in an inverted arrangement separated by a mutated ITR-like structure. This allows circumvention of the time lag associated with second-strand synthesis, because after uncoating, these molecules readily fold into double-stranded templates due to their self-complementary nature. The use of such self-complementary (sc) vectors is expected to increase the efficiency of gene transfer. 5, 13 Recently, a novel serotype AAV8, whose capsid sequence was isolated from the rhesus monkey, has generated significant interest, because of its wide tissue tropism and exceptionally high rate of gene transfer in neonatal mouse brain, 14 skeletal and cardiac muscles, 15 and pancreatic acinar cells. 16 Studies in the non-human primate have shown AAV2/8-mediated transgene expression in the liver to be more rapid and substantially higher than AAV2 and 2/5. 17 The number of transduced hepatocytes 6 weeks p.i. is approximately fourfold higher with AAV2/8 compared to AAV2/2 at the same vector dose. When the dose of AAV2/8 was increased sixfold, this resulted in a twofold higher hepatocyte transduction from 13.1 to 30%. 11 This was further increased to 90% when AAV2/8 was used in its sc form. 18 In this study we evaluated the transduction profile of ss and scAAV2/8 carrying the GFP gene after subretinal, intravitreal and intracameral injection. Fundoscopic examination of animals following subretinal injection of ssAAV2/8 showed GFP fluorescence increasing steadily from day 5 p.i. before reaching a plateau after 7 weeks ( Figure 1 ). This level of GFP fluorescence was maintained until 11 weeks p.i., the latest time point examined. Luminance was quantified as a measure of GFP fluorescence using Image Pro software ( Figure 2 ). Histological examination of eyes showed RPE and photoreceptor cell transduction following subretinal delivery of rAAV2/8. RPE cell transduction was visible as early as 24 h p.i. whereas photoreceptor transduction was apparent by day 5 p.i. (Figure 3 ). At 5 weeks p.i., GFP fluorescence was visible in greater numbers of RPE and photoreceptor cells, with equally strong fluorescence present in both cell types. Following intravitreal and intracameral delivery of ssAAV2/8, no GFP expression was detectable, indicating that ssAAV2/8 cannot transduce cells in the inner retina or anterior segment. Although subretinal administration of ssAAV2/8 showed fundus fluorescence at 5 days p.i., injection of titre-matched ssAAV2 and ssAAV2/5 did not result in detectable fluorescence until 1-2 weeks p.i. (data not shown). The levels of fluorescence after ssAAV2/5 and ssAAV2 administration stabilized by 4-6 and 6-8 weeks p.i., respectively (data not shown). GFP expression levels following ssAAV2/8 injection were much higher than Figure 1 In vivo imaging of green fluorescent protein (GFP) fluorescence after subretinal delivery of ssAAV2/8 (left eye) and scAAV2/8 (right eye). Expression was detected 5 days p.i., with self-complementary (sc) vector displaying higher reporter gene expression by day 9 p.i. GFP expression stabilized after 7 weeks. Fluorescence remained higher with sc than with single-stranded (ss) vector until the last time point examined, 11 weeks p.i., with no evidence of retinal toxicity. Subretinal injections in two animals per serotype were performed as described previously.
19 AAV2 and 2/5 vectors 7,20,21 and AAV2/8 22 were produced as described previously. The titres of all ss and sc vector suspensions were matched to 1.5 Â 10 10 particles per ml. All fundus photographs were exposed for 19.7 s prior to image capture. For ss and scAAV2/ 8-injected animals, the same animals were used for weekly comparison of reporter gene expression. (Figure 4a ). The luminance values in AAV2/5-injected eyes were 9.0 (ss) and 11.3
(sc), while in AAV2-injected eyes the values were 8.0 (ss) and 17.4 (sc). The luminance values for the AAV8-treated eyes were 65.9 (ss) and 151.6 (sc), respectively. Figure 4b shows histological examination of injected eye at time points of stable and peak expression. ssAAV2/8 transduced far more RPE cells and photoreceptors than ssAAV2 and ssAAV2/5. The transduction level of photoreceptor cells and RPE cells appears equal in the AAV2/8-transduced cells, in contrast to the AAV2/5-and AAV2-injected eyes, where the RPE showed higher levels of GFP expression. The transduction properties of scAAV vectors after delivery into the anterior chamber, subretinal space or vitreous cavity were compared with ss vectors. Nine days after subretinal administration, scAAV2/8-injected eyes showed comparatively higher levels of fluorescence than its ss counterpart (Figure 2 ). Both vectors reached stable levels of expression by 7 weeks p.i., after which GFP fluorescence from scAAV2/8 remained twofold higher than that of its ss vector ( Figure  2 ). Histological examination demonstrates a greater number of RPE and photoreceptor cells transduced with scAAV2/8 compared with ssAAV2/8 vector ( Figure 4 ). scAAV2/2 and 2/5 appeared to have the same onset of transgene expression as their ss counterparts on fundoscopic examination. However, compared with their ss counterparts both sc vector pseudotypes displayed higher levels of GFP fluorescence on fundus imaging, and a greater number of transduced RPE and photoreceptors ( Figure 4 ). After intravitreal and intracameral administration we found higher GFP expression in the ciliary body and, retinal ganglion cells and optic nerve with scAAV2 compared with ss vector (data not shown). Vector choice is a key factor influencing the success of gene replacement therapy for animal models of disease, such as inherited retinal degenerations. Our findings show subretinally injected AAV2/8 to have strong transduction properties within the murine retina, with Ocular transduction using AAV2/8 M Natkunarajah et al regard to transduction efficiency, onset of transgene expression and the maximal level of expression. Its rapid onset of reporter gene expression may be attributed, in part, to its fast rate of uncoating within the nucleus, thus facilitating single-stranded to double-stranded vector genome formation, making it stable and amenable to transcription. In contrast slow uncoating of AAV2 leads to its degradation and poor transduction efficiency.
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This is thought to be influenced by the rate and relative efficiency of cleavage of the various viral capsids by cathepsins. As yet the rate of AAV5 viral uncoating is unknown, though it is believed to be cathepsin dependent. 23 In comparison with AAV2 and AAV2/5, AAV2/ 8-injected eyes show much higher levels of fluorescence as measured by luminance levels on in vivo fundus images. This could be because of higher levels of reporter gene itself, and/or because of increased photoreceptor and RPE cell transduction. The vastly superior gene delivery to the outer retina by AAV2/8 vector is similar to findings reported in other mouse tissues, such as hepatocytes, skeletal muscle and heart. 24, 25 Allocca et al.
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have also recently reported similar efficiency of transduction and transgene expression following AAV2/8 administration in the retina. Packaging AAV genomes as self-complementary duplex strands allows for immediate as well as long-term transgene expression by increasing genomic stability and avoiding second-strand synthesis which is generally thought to be the ratelimiting step for AAV-mediated transgene expression. 27 We found that at any given time point all of the scAAV vectors tested in this study mediated higher levels of transgene expression than their single-stranded counterparts, although this was most evident for scAAV2/8; this phenomenon is most likely due to a higher stability of dsDNA in the nucleus compared with ssDNA. Surprisingly, the time point at which the peak of expression reached was similar for ssAAV and scAAV vectors. While the rate of onset of expression early after transduction is clearly higher for scAAV8 than ssAAV8, between 3 and 7 weeks p.i. the rate of expression increases similarly for both forms of the virus (Figure 2 ). These results suggest that for a substantial fraction of the scAAV8 particles the absence of second-strand formation allows a faster onset of expression, whereas for the remainder of the vector this step is not rate limiting. The slow uncoating of some vector particles might be responsible for the slower phase of transgene expression. The higher transduction efficiency conferred by a stable double-stranded selfcomplementary genome has implications for its in vivo use. It enables the use of a lower viral dose to reach the same therapeutic transgene levels achieved by ssAAV vectors, minimizing immunological responses and avoiding toxicity. Unfortunately its self-complementary structure limits the transgene cassette size to 2.3 kb, imposing restrictions on the range of therapeutic transgenes able to be accommodated. However, genes that might be packaged in sc vectors include genes that encode many small neurotrophic and immunomodulatory factors and siRNA molecules. 28, 29 Our findings and other work in the murine 30-32 rat 33, 34 and canine retina 35 have shown AAV2-and 2/5-mediated GFP expression to be stronger in the RPE layer relative to the outer nuclear layer (ONL), suggesting that AAV2 and 2/5 have a higher tropism for RPE cells than for photoreceptors. AAV2/8 demonstrates an equal tropism as GFP signal intensity appears similar for the two cell types. The inherent transduction properties of AAV2 and 2/5 may in part explain their success in the treatment of animal models that are primarily RPE based. For example Mertk and RPE65 mutations that lead to blindness through secondary photoreceptor cell degeneration have both been successfully treated with AAV2-mediated gene replacement therapy targeted to restore RPE cell function. Both treated animal models have shown a slowing of retinal degeneration, resulting in both functional and histological improvements. 36, 37 However, treatment of animal models of retinal degenerations that primarily affect photoreceptors has been more limited. For example, the treatment of Prph2À/À mice showed functional improvement of the photoreceptor cells without a concomitant slowing of the rate of photoreceptor loss, even upon repeated subretinal injections of AAV2.rho.rds. 38 The higher transduction efficiency of AAV2/8 relative to AAV2 and 2/5 might facilitate the treatment of animal models of severe retinal degeneration due to photoreceptor gene defects and thus provide a valuable vector system for the treatment of early onset inherited retinal degenerations.
